Linking U.S. prescription drug prices to those paid in other nations could cut costs in half

Photo: Shana Novak/Getty Images

Linking the cost of prescription drugs in the United States to the prices paid in other high-income nations could have reduced American spending for the drugs by at least half in 2020, according to a new RAND Corporation study.
 
Modeling a proposal that would cap U.S. prices at 120% of what is paid in six other nations, researchers found that such a move would have cut U.S. spending on insulins and 50 top brand-name drugs by 52% during 2020 – a savings of $83.5 billion. These savings are on top of already-lower U.S. "net" prices after rebates negotiated between drug companies and insurers. 
 
The findings are published online by the Journal of the American Medical Association.

WHAT'S THE IMPACT?

High prescription drug prices have important implications for the American healthcare system, driving up overall costs, burdening some patients with high co-pays and causing many people to forgo needed medications.

The Elijah E. Cummings Lower Drug Costs Now Act would allow the U.S. Secretary of Health and Human Services to negotiate prices with drug manufacturers on behalf of Medicare and private insurers, up to a cap of 120% of prices in six high-income countries: Australia, Canada, France, Germany, Japan and the U.K. The bill was first introduced in Congress in 2019.

Such negotiations would initially apply to all insulins and at least 25 single-source, brand-name drugs selected by the Secretary

Prices for brand-name drugs are higher in the U.S. compared to other high-income countries, most of which regulate drug prices. However, inconsistent availability of data on U.S. net prices (the prices insurers pay after rebates and other discounts) complicates international comparisons of brand-name drug prices.

RAND researchers compared what 2020 spending would have been if the U.S. bought insulins and 50 top single-source, brand-name drugs at U.S. manufacturer prices, U.S. net prices after rebates, and at H.R. 3 international ceiling prices. The authors combined IQVIA MIDAS data on drug volumes and prices in other countries with SSR Health data on U.S. net sales.

Savings from international reference pricing varied across different groups of drugs.

Spending at international rather than U.S. net prices would have reduced spending by 53.7% for oncology drugs, where discounts from rebates in the U.S. are relatively small. For insulins, where U.S. rebates are substantial, spending at international prices would have still lowered spending by 44.4%.

Researchers said that while international reference pricing would yield considerable savings for U.S. consumers, other important considerations around the design and implementation of drug price regulation must be considered as a part of any such program. Those issues include incentives for research and development, industry launch and pricing strategies, and demand responses to lower prices.

THE LARGER TREND

Just this week, HHS Secretary Xavier Becerra released a plan intended to lower drug prices, in part by allowing the HHS head to negotiate Medicare Part B and Part D drug prices directly with pharmaceutical companies, and make those prices available to other purchasers.

The Drug Pricing Plan, as it's called, is part of a broader initiative stemming from President Joe Biden's Executive Order on Promoting Competition in the American Economy, which also created the White House Competition Council tasked with coordinating, promoting and advancing federal efforts to address overconcentration, monopolization and unfair competition in or directly affecting the American economy. 

The underlying principles behind the plan, according to HHS, are competition, innovation and transparency.

According to HHS data, Americans pay more than $1,500 per person for prescription drugs, far higher than other comparable nations. And prices for brand name drugs are rising faster than the rate of inflation, leading many to not take their medications as prescribed due to their cost. HHS has identified lack of competition as a key driver of these rising drug costs.
 

Twitter: @JELagasse
Email the writer: jeff.lagasse@himssmedia.com